Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 17, 2026 by admin
<![CDATA[Check out new phase 2 dose-ranging study data evaluating alixorexton in patients with narcolepsy type 2. ]]>
CategoriesUncategorized TagsAcademic research, Clinical trial, Sleep-related parasomnias

Post navigation

Previous PostPrevious Digital Platform to Provide Health Data Feedback for Neurorehabilitation Patients: User-Centered Development and Proof-of-Concept Usability Study
Next PostNext STAT+: DOJ’s swift win in OhioHealth case should have hospitals studying their contracts, experts say
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.